Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 3
1976 2
1977 1
1980 1
1981 1
1982 1
1984 1
1985 1
1986 2
1987 1
1989 1
1992 1
1994 3
1995 1
1996 1
1997 1
2004 1
2006 2
2008 2
2009 3
2010 2
2011 2
2013 4
2014 2
2015 1
2016 1
2017 1
2018 1
2020 1
2021 4
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

49 results

Results by year

Filters applied: . Clear all
Page 1
Macrophage-targeted nanomedicine for the diagnosis and treatment of atherosclerosis.
Chen W, Schilperoort M, Cao Y, Shi J, Tabas I, Tao W. Chen W, et al. Nat Rev Cardiol. 2022 Apr;19(4):228-249. doi: 10.1038/s41569-021-00629-x. Epub 2021 Nov 10. Nat Rev Cardiol. 2022. PMID: 34759324 Free PMC article. Review.
In this Review, we highlight efforts in the past two decades to develop imaging techniques and to therapeutically manipulate macrophages in atherosclerotic plaques with the use of rationally designed nanoparticles. We review the latest progress in nanoparticle-based imagin …
In this Review, we highlight efforts in the past two decades to develop imaging techniques and to therapeutically manipulate macrophages in …
Towards precision medicine in heart failure.
Weldy CS, Ashley EA. Weldy CS, et al. Nat Rev Cardiol. 2021 Nov;18(11):745-762. doi: 10.1038/s41569-021-00566-9. Epub 2021 Jun 9. Nat Rev Cardiol. 2021. PMID: 34108678 Review.
Indeed, we are on the verge of a new era in HF in which insights into the biology of myocardial disease can be matched to an understanding of the genetic predisposition in an individual patient to inform precision approaches to therapy. In this Review, we summarize the bio …
Indeed, we are on the verge of a new era in HF in which insights into the biology of myocardial disease can be matched to an understanding o …
Combination therapy in pulmonary arterial hypertension: a meta-analysis.
Bai Y, Sun L, Hu S, Wei Y. Bai Y, et al. Cardiology. 2011;120(3):157-65. doi: 10.1159/000334431. Epub 2011 Dec 29. Cardiology. 2011. PMID: 22212696 Review.
The objective was to analyze completed trials assessing the efficacy and safety of treating PAH with combination therapy. METHODS: We performed a meta-analysis of all randomized controlled combination therapy trials that evaluated efficacy and safety in PAH patients …
The objective was to analyze completed trials assessing the efficacy and safety of treating PAH with combination therapy. METHODS: We …
Pathophysiology and treatment of congestive heart failure.
Just H, Drexler H, Hasenfuss G. Just H, et al. Cardiology. 1994;84 Suppl 2:99-107. doi: 10.1159/000176462. Cardiology. 1994. PMID: 7954551 Review.
Pharmacotherapy of heart failure is likely to be most efficacious when individually tailored to the prevailing pathophysiological derangements. Their diagnostic definition and understanding of the mechanisms involved affords the greatest opportunity for their correction an …
Pharmacotherapy of heart failure is likely to be most efficacious when individually tailored to the prevailing pathophysiological der …
Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006: diagnosis and management.
Arnold JM, Liu P, Demers C, Dorian P, Giannetti N, Haddad H, Heckman GA, Howlett JG, Ignaszewski A, Johnstone DE, Jong P, McKelvie RS, Moe GW, Parker JD, Rao V, Ross HJ, Sequeira EJ, Svendsen AM, Teo K, Tsuyuki RT, White M; Canadian Cardiovascular Society. Arnold JM, et al. Can J Cardiol. 2006 Jan;22(1):23-45. doi: 10.1016/s0828-282x(06)70237-9. Can J Cardiol. 2006. PMID: 16450016 Free PMC article.
Management of heart failure begins with an accurate diagnosis, and requires rational combination drug therapy, individualization of care for each patient (based on their symptoms, clinical presentation and disease severity), appropriate mechanical interventio …
Management of heart failure begins with an accurate diagnosis, and requires rational combination drug therapy, individu …
Rational Medical Therapy Is the Key to Effective Cardiovascular Disease Prevention.
Spence JD. Spence JD. Can J Cardiol. 2017 May;33(5):626-634. doi: 10.1016/j.cjca.2017.01.003. Epub 2017 Jan 19. Can J Cardiol. 2017. PMID: 28449833 Review.
A particularly useful phenotype is carotid plaque burden. In high-risk patients, intensive lipid-lowering therapy aimed to prevent progression of carotid plaque can reduce the risk of stroke or myocardial infarction by > 80%. Available therapies, used more rationally …
A particularly useful phenotype is carotid plaque burden. In high-risk patients, intensive lipid-lowering therapy aimed to prevent pr …
Patient-Centred Care of Older Adults With Cardiovascular Disease and Multiple Chronic Conditions.
Kim DH, Rich MW. Kim DH, et al. Can J Cardiol. 2016 Sep;32(9):1097-107. doi: 10.1016/j.cjca.2016.04.003. Epub 2016 Apr 20. Can J Cardiol. 2016. PMID: 27378591 Free PMC article. Review.
Each treatment recommended by a clinical practice guideline for a single cardiovascular disease might be rational, but the combination of all evidence-based recommendations can be impractical or even harmful to individuals with multimorbidity. ...It might be necessary to d …
Each treatment recommended by a clinical practice guideline for a single cardiovascular disease might be rational, but the combinatio …
Taking the Pulse of Atrial Fibrillation: A Practical Approach to Rate Control.
Aguilar M, Nattel S. Aguilar M, et al. Can J Cardiol. 2018 Nov;34(11):1526-1530. doi: 10.1016/j.cjca.2018.07.015. Epub 2018 Jul 23. Can J Cardiol. 2018. PMID: 30404755
Despite its extensive use, the rational basis for rate-control therapy is underemphasized in clinical teaching and practice. In this article, we aim to provide evidence-based thoughts on important practical aspects of rate-control therapy in AF by reviewing 5 …
Despite its extensive use, the rational basis for rate-control therapy is underemphasized in clinical teaching and practice. I …
Canadian Cardiovascular Society guidelines for the diagnosis and management of stable ischemic heart disease.
Mancini GB, Gosselin G, Chow B, Kostuk W, Stone J, Yvorchuk KJ, Abramson BL, Cartier R, Huckell V, Tardif JC, Connelly K, Ducas J, Farkouh ME, Gupta M, Juneau M, O'Neill B, Raggi P, Teo K, Verma S, Zimmermann R; Canadian Cardiovascular Society. Mancini GB, et al. Can J Cardiol. 2014 Aug;30(8):837-49. doi: 10.1016/j.cjca.2014.05.013. Epub 2014 May 28. Can J Cardiol. 2014. PMID: 25064578
The suggestions and recommendations are intended to be of relevance to primary care and specialist physicians with an emphasis on rational deployment of diagnostic tests, expedited implementation of long- and short-term medical therapy, timely consideration of revas …
The suggestions and recommendations are intended to be of relevance to primary care and specialist physicians with an emphasis on rationa …
Infarct-related artery patency and long-term effects on left ventricular remodelling.
Visser CA. Visser CA. Cardiology. 1997;88 Suppl 1:26-35; discussion 36. doi: 10.1159/000177456. Cardiology. 1997. PMID: 9118165 Review.
In particular, there is increasing evidence that remodelling can be prevented through the use of late reperfusion therapy and therapy aimed at maintaining IRA patency in the long term. ...Prospective clinical trials are required to evaluate late reperfusion thera …
In particular, there is increasing evidence that remodelling can be prevented through the use of late reperfusion therapy and ther …
49 results